Search results

Articles (6)

Journals (0)

1-6 of 6 results for MONALEESA-2

Sort by:

Relevance

Select all

Sort by:

Relevance

Open accessResearch articleFirst published 2023

Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2− advanced breast cancer

Komal Jhaveri, Joyce O’Shaughnessy, Peter A. Fasching [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2023

Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison

Hope S. Rugo, Victoria Harmer, Joyce O’Shaughnessy [...]

Therapeutic Advances in Medical Oncology

Open accessEditorialFirst published 2018

Managing advanced HR-positive,HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?

Lorenzo Rossi, Amelia McCartney, Emanuela Risi [...]

Therapeutic Advances in Medical Oncology

Restricted accessCase reportFirst published December, 2021

Ribociclib induced acute kidney injury: A case report

Ilkay Gulturk, Mesut Yilmaz, Aykut Ozmen [...]

Journal of Oncology Pharmacy Practice

Restricted accessArticle commentaryFirst published September, 2020

The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer

Jacopo Giuliani, Andrea Bonetti

Journal of Oncology Pharmacy Practice

Open accessResearch articleFirst published 2021

Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2− locally advanced or metastatic breast cancer: a Brazilian private payer perspective

Anna Maria Buehler, Gabriela Castilho, Pierre-Alexandre Dionne [...]

Therapeutic Advances in Medical Oncology

Search results

Articles (6)

Journals (0)

1-6 of 6 results for MONALEESA-2

Sort by:

Relevance

Select all

Sort by:

Relevance

Open accessResearch articleFirst published 2023

Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2− advanced breast cancer

Komal Jhaveri, Joyce O’Shaughnessy, Peter A. Fasching [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2023

Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison

Hope S. Rugo, Victoria Harmer, Joyce O’Shaughnessy [...]

Therapeutic Advances in Medical Oncology

Open accessEditorialFirst published 2018

Managing advanced HR-positive,HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?

Lorenzo Rossi, Amelia McCartney, Emanuela Risi [...]

Therapeutic Advances in Medical Oncology

Restricted accessCase reportFirst published December, 2021

Ribociclib induced acute kidney injury: A case report

Ilkay Gulturk, Mesut Yilmaz, Aykut Ozmen [...]

Journal of Oncology Pharmacy Practice

Restricted accessArticle commentaryFirst published September, 2020

The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer

Jacopo Giuliani, Andrea Bonetti

Journal of Oncology Pharmacy Practice

Open accessResearch articleFirst published 2021

Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2− locally advanced or metastatic breast cancer: a Brazilian private payer perspective

Anna Maria Buehler, Gabriela Castilho, Pierre-Alexandre Dionne [...]

Therapeutic Advances in Medical Oncology